Literature DB >> 17478762

The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.

Seung-Sang Ko1, Youn-Sun Na, Chan-Seok Yoon, Ji-Young Park, Hye-Sun Kim, Min-Hee Hur, Hae-Kyung Lee, Yi-Kyung Chun, Sung-Soo Kang, Byeong-Woo Park, Jee-Hyun Lee.   

Abstract

We conducted this study to examine whether the expression of c-erbB-2 and p53 is the prognostic indicator for patients with early-stage breast cancer in which axillary lymph node metastasis is absent. We examined 326 patients with early-stage breast cancer in which axillary lymph node metastasis is absent. Tissue microarrays were constructed. Following this, immunohistochemical staining was done for estrogen receptor (ER), progesterone receptor (PR), c-erbB2, and p53. The results were as follows: (1) expression of c-erbB-2 was correlated with other clinicopathologic factors (eg, patient's age, presence of menopause, tumor size, histologic and nuclear grade, and presence of hormone receptors such as ER and PR); and (2) expression of p53 was correlated with survival rate, patient's age, presence of menopause, and tumor size. However, these results were not statistically significant. In conclusion, our results indicate that expression of c-erbB-2 and p53 did not have any prognostic value in patients with early-stage breast cancer in which axillary lymph node metastasis is absent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478762     DOI: 10.1177/1066896906299124

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  6 in total

1.  Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma.

Authors:  Lang Hu; Gang Chen; Hongping Yu; Xiaoqiang Qiu
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

2.  Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.

Authors:  Caigang Liu; Hao Zhang; Chen Shuang; Yang Lu; Feng Jin; Huimian Xu; Ping Lu
Journal:  Med Oncol       Date:  2009-08-06       Impact factor: 3.064

3.  HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters.

Authors:  Reşit Doğan Köseoğlu; Fatma Markoç; Ahmet Müslehiddinoğlu; Ayşe Burcu İleri; Faik Alev Deresoy; İlker Etikan
Journal:  Eur J Breast Health       Date:  2018-10-24

4.  Testing for HER2 in Breast Cancer: A Continuing Evolution.

Authors:  Sejal Shah; Beiyun Chen
Journal:  Patholog Res Int       Date:  2010-12-06

5.  Malignant transformation and stromal invasion from normal or hyperplastic tissues: true or false?

Authors:  Yan-Gao Man; Michael Grinkemeyer; Mina Izadjoo; Alexander Stojadinovic
Journal:  J Cancer       Date:  2011-07-23       Impact factor: 4.207

6.  Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

Authors:  S M Tovey; S Brown; J C Doughty; E A Mallon; T G Cooke; J Edwards
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.